Edition:
United States

Dyax Corp (DYAX.OQ)

DYAX.OQ on NASDAQ Stock Exchange Global Market

38.41USD
21 Jan 2016
Change (% chg)

-- (--)
Prev Close
$38.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
--
52-wk Low
--

DYAX.OQ

Chart for DYAX.OQ

About

Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma... (more)
No analyst recommendations are available for DYAX.OQ.

Overall

Beta: 1.42
Market Cap(Mil.): $5,653.36
Shares Outstanding(Mil.): 147.18
Dividend: --
Yield (%): --

Financials

  DYAX.OQ Industry Sector
P/E (TTM): -- 39.80 37.05
EPS (TTM): -0.21 -- --
ROI: -11.53 -5.86 14.35
ROE: -14.14 -4.70 15.56

REFILE-MOVES-Barclays hires top U.S. healthcare bankers from Deutsche -sources

March 29 Jason Haas and David Levin, Deutsche Bank AG's top U.S. healthcare investment bankers, have resigned to join Barclays Plc and take leading roles in its healthcare practice, according to people familiar with the matter.

Mar 29 2016

CORRECTED-MOVES-Barclays hires top U.S. healthcare bankers from Deutsche -sources

March 29 Jason Haas and David Levin, Deutsche Bank AG's top U.S. healthcare investment bankers, have resigned to join Barclays Plc and take leading roles in its healthcare practice, according to people familiar with the matter.

Mar 29 2016

Drugmaker Shire delivers earnings beat amid deal-making push

LONDON Drugmaker Shire reported better-than-expected profit in the last quarter of 2015, a period when management could have been distracted by buying rare disease specialist Dyax and the final stages of its $32 billion pursuit of Baxalta International.

Feb 11 2016

UPDATE 2-Drugmaker Shire delivers earnings beat amid deal-making push

* Shares up 2.8 percent (Adds CEO comments, analyst reaction, updates shares)

Feb 11 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Jefferson Research
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.